Aptevo to Participate in March 2026 Conferences
Rhea-AI Summary
Aptevo Therapeutics (NASDAQ:APVO) will participate in two March 2026 conferences: the 38th Annual Roth Conference (Dana Point, CA) and BIO-Europe Spring (Lisbon, Portugal).
Aptevo incoming CEO Jeff Lamothe will join a company fireside chat on March 23, 2026 at 1:30 PM PT. Michelle H. Nelson, PhD, will present Aptevo's trispecific ADAPTIR-FLEX molecules on March 24, 2026 at 1:15 PM ET. Events include investor meetings, panels, and partnering opportunities.
Positive
- None.
Negative
- None.
News Market Reaction – APVO
On the day this news was published, APVO declined 3.64%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer biotech names show mixed moves (e.g., GRI +2.71%, OGEN +3.68%, ONCO -2.15%), indicating no clear sector-wide trend linked to this conference update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Clinical data update | Positive | -22.8% | Interim AML data showed 86% clinical benefit rate with no CRS reported. |
| Feb 03 | Leadership transition | Positive | -10.3% | CEO transition and board changes alongside clinical progress and 2029 runway. |
| Jan 09 | Equity line financing | Positive | +5.0% | Entered $60M equity line with Yorkville to extend funding runway into 2029. |
| Dec 26 | Reverse stock split | Negative | -34.7% | 1-for-18 reverse split reduced outstanding shares from ~18M to ~1M. |
| Dec 09 | Clinical data update | Positive | -7.5% | ASH data showed high ORR and CR/CRi rates with strong safety profile. |
APVO has often traded lower on positive clinical and corporate updates, with several notable sell-offs following favorable news.
Over the past six months, Aptevo reported multiple positive clinical milestones for mipletamig and expanded its financing flexibility, yet share reactions were often negative. On Dec 9, 2025, strong AML remission and safety data were followed by a -7.46% move. Interim frontline AML data on Mar 10, 2026 with high clinical benefit coincided with a -22.79% reaction. Leadership transitions and a pipeline/running-into-2029 update on Feb 3, 2026 also saw a -10.34% move, while the Jan 9, 2026 equity line news led to a +5% gain.
Market Pulse Summary
This announcement outlines Aptevo’s participation in March investor and partnering conferences, including the 38th Annual Roth Conference and BIO-Europe Spring. These events typically offer visibility with investors and potential partners but do not change underlying fundamentals on their own. In context, investors may track how the company discusses its ADAPTIR and ADAPTIR-FLEX platforms, trispecific programs, leadership transition effective in 2026, and previously reported AML data and financing structures.
Key Terms
immune-oncology medical
trispecific molecules medical
immunobiology medical
AI-generated analysis. Not financial advice.
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced its participation in the following March conferences:
The 38th Annual Roth Conference
March 22-24, 2026, in Dana Point, CA. Aptevo incoming President and Chief Executive Officer Jeff Lamothe will participate in a Company-focused fireside chat with analyst Jonathan Aschoff. The discussion will occur on Monday, March 23, 2026, at 1:30 PM Pacific Time, and will be broadcast live at the conference.
The Roth conference will consist of 1-on-1 and small group meetings, analyst-selected fireside chats, industry keynotes, and panels with executive management attending from hundreds of private and public companies across a variety of growth sectors.
BIO-Europe Spring
March 23-25, 2026, in Lisbon, Portugal. Aptevo will deliver a company presentation highlighting its proprietary trispecific molecules developed from the Company's ADAPTIR-FLEX platform. Michelle H. Nelson, PhD, Senior Director, Immunobiology, will present on Tuesday, March 24, 2026, at 1:15 PM Eastern Time (5:15 PM Central European Time).
BIO-Europe Spring is one of the premier partnering events for the life sciences industry, bringing together biotechnology and pharmaceutical companies, investors, and strategic partners to explore collaboration and licensing opportunities.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates and six preclinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax and azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, the possibility and timing of interim data readouts for ALG.APV-527, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises, geopolitical risks, including the current war between Russia and Ukraine, the United States and Iran, and any other military event that could evolve out of any of the current conflicts, and macroeconomic conditions such as economic uncertainty, imposition of tariffs, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
CONTACT:
Miriam Weber Miller
Vice President, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
FAQ
When will Aptevo (APVO) present at the Roth Conference in March 2026?
What will Aptevo (APVO) present at BIO-Europe Spring 2026 and when?
How can investors watch Aptevo's (APVO) Roth Conference fireside chat on March 23, 2026?
Will Aptevo's (APVO) conference presentations include investor meetings or partnering opportunities?
Who from Aptevo (APVO) will speak at the March 2026 conferences?
